PCRX
NASDAQPacira BioSciences
$36.39
+11.19 (+44.40%)
2026-10-08 00:00
Healthcare
Drug Manufacturers - Specialty & Generic
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$961.1M
P/E Ratio
68.9
52W Low
52W High
$18.80
$36.40
Volume
28.9M
Analyst Rating
Hold
Target: $29
9 Analyst Ratings
Strong Buy
0
Buy
0
Hold
9
Sell
0
Price Target Range
Low: $29
Avg: $29
High: $30
About Pacira BioSciences
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld c...
Employees
825
Website
pacira.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $726.4M | 4.6% | $7.0M | $167.3M |
| 2024 | $701.0M | -10.5% | -$99.6M | $200.0M |
| 2023 | $675.0M | 13.0% | $42.0M | $169.8M |
| 2022 | $666.8M | 9.0% | $15.9M | $175.3M |
| 2021 | $541.5M | 16.6% | $42.0M | $171.6M |
| 2026 Q2 | $192.4M | 2.2% | $4.7M | $58.8M |
| 2026 Q1 | $177.4M | 2.6% | $2.9M | $28.4M |
| 2025 Q4 | $196.9M | 1.6% | $1.6M | $43.9M |
| 2025 Q3 | $179.5M | 3.5% | $5.4M | $64.7M |
| 2025 Q2 | $181.1M | 4.7% | -$4.8M | $14.7M |
| 2025 Q1 | $168.9M | 1.2% | $4.8M | $44.0M |
| 2024 Q4 | $187.3M | 13.2% | $16.0M | $35.2M |
| 2024 Q3 | $168.6M | -82.8% | -$143.5M | $58.0M |